

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wolfgang E. BERDEL *et al.*

Appln. No.: 10/569,076

Filing Date: August 23, 2006

Conf. No.: 7498

Art Unit: 1647

Examiner: Marianne P. Allen

Atty. Docket: P30712US00 / 20490.003

For: Fusion Peptides, and Use Thereof in Antivascular Tumor Therapy

Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO/SB/08a. Copies of the listed documents are attached.


It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

CERTIFICATION AND/OR FEE

Because this Information Disclosure Statement is being submitted after issuance of the first action on the merits of the above-captioned application, authorization to charge the statutory fee of \$180 to counsel's deposit account is given in the accompanying transmittal letter.

Respectfully submitted,

Filed: November 17, 2008


Kristan L. Lansbery (Reg. No. 53,183)
David R. Marsh (Reg. No. 41,408)

ARNOLD & PORTER LLP
Attn: IP Docketing
555 Twelfth Street, N.W.
Washington, DC 20004-1206
Tel.: 202.942.5000
Fax: 202.942.5999